Consensus Moderna, Inc.

Equities

MRNA

US60770K1079

Market Closed - Nasdaq 04:00:00 2024-07-22 pm EDT 5-day change 1st Jan Change
122.5 USD +1.12% Intraday chart for Moderna, Inc. +0.84% +23.18%

Evolution of the average Target Price on Moderna, Inc.

Price target over the last 5 years

History of analyst recommendation changes

ad6d76159d2e7ec49cf04ddd03c96.vNny6am0vSlDJSasL5aUZ97XIZ8yHkEeYYSC4QUOe-w.i7zF3cfa8n4La37HaePkFqa4QM1zcRV4Ke63s25lFKXrvL6g3MfrEXNMYw~633740effe27d01907b80a7d19088ef4
Moderna Insider Sold Shares Worth $1,842,651, According to a Recent SEC Filing MT
Moderna Insider Sold Shares Worth $1,756,177, According to a Recent SEC Filing MT
Redburn Raises Moderna's Price Target to $117 From $116 MT
Argus Raises Moderna's Price Target to $150 From $115 MT
JPMorgan Raises Price Target on Moderna to $96 From $85 MT
Oppenheimer Raises Price Target on Moderna to $179 From $163 MT
Moderna Insider Sold Shares Worth $30,087,339, According to a Recent SEC Filing MT
Jefferies Adjusts Price Target on Moderna to $180 From $155, Keeps Buy Rating MT
RBC Raises Moderna's PT to $160 From $135 Amid RSV Vaccine Approval From US FDA, Keeps Outperform Rating MT
RBC Raises Price Target on Moderna to $160 From $135 Amid RSV Vaccine Approval From FDA, Keeps Outperform Rating MT
MODERNA : Oddo BHF raises its target price on the stock CF
ANALYSTS RECOMMENDATIONS : Best Buy, Dell Technologies, Moderna, AMD, National Grid... Our Logo
Moderna Insider Sold Shares Worth $2,901,585, According to a Recent SEC Filing MT
RBC Raises Moderna's Price Target to $160 From $135 MT
Moderna Insider Sold Shares Worth $1,909,863, According to a Recent SEC Filing MT
Moderna Insider Sold Shares Worth $1,912,350, According to a Recent SEC Filing MT
Arbutus Biopharma Urged to Stop Share Issuances, Explore Alternatives for Hepatitis B Program MT
ANALYST RECOMMENDATIONS : Nike, Roblox, Starbucks, Walmart, Deckers Outdoor... Our Logo
Evercore ISI Initiates Moderna With In Line Rating, $120 Price Target MT
Moderna Insider Sold Shares Worth $1,825,220, According to a Recent SEC Filing MT
Deutsche Bank Raises Moderna's Price Target to $85 From $70 MT
UBS Adjusts Moderna Price Target to $151 From $143, Maintains Buy Rating MT
Moderna Insider Sold Shares Worth $1,663,855, According to a Recent SEC Filing MT
Jefferies Adjusts Price Target on Moderna to $155 From $125 MT
Oppenheimer Adjusts Price Target on Moderna to $163 From $142 MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
122.5 USD
Average target price
145.9 USD
Spread / Average Target
+19.10%
High Price Target
310 USD
Spread / Highest target
+153.06%
Low Price Target
62 USD
Spread / Lowest Target
-49.39%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Moderna, Inc.

Argus
JPMorgan Chase
Oppenheimer
Jefferies & Co.
RBC Capital Markets
Evercore ISI
Deutsche Bank Securities
UBS
Goldman Sachs
Leerink Partners
Morgan Stanley
Redburn
HSBC
Canaccord Genuity
RBC Luca Issi
TD Cowen
William Blair & Co.
Guggenheim
SVB Securities LLC
Cowen
Chardan Research
Piper Sandler
SVB Leerink
BofA Securities
Wolfe Research
Barclays
Chardan
J.P. Morgan Chase
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
  1. Stock Market
  2. Equities
  3. MRNA Stock
  4. Consensus Moderna, Inc.